SCHEMBL1498293

SCHEMBL1498293

CC1(N)CCC(F)(S(=O)(=O)c2cccc(C(F)(F)F)c2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 2/20 0.46
▸ CA2 P00918 2/20 0.46
▸ MMP1 P03956 1/20 0.46
▸ MMP2 P08253 1/20 0.46
▸ MMP9 P14780 1/20 0.46
▸ MMP8 P22894 1/20 0.46
▸ MMP13 P45452 1/20 0.46
▸ HTT P42858 1/20 0.40
▸ NPSR1 Q6W5P4 2/20 0.40
▸ KDM1A O60341 2/20 0.39
▸ SLC1A3 P43003 1/20 0.39
▸ SLC1A2 P43004 1/20 0.39
▸ HSD17B2 P37059 1/20 0.39
▸ CA12 O43570 1/20 0.39
▸ CA9 Q16790 1/20 0.39
▸ AKR1B1 P15121 1/20 0.39
▸ LMNA P02545 1/20 0.38
▸ PKM P14618 1/20 0.38
▸ PKLR P30613 1/20 0.38
▸ HSP90AA1 P07900 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1498299 0.87 CA1 (0.42) CA1CA2MMP1MMP2MMP9
SCHEMBL27879701 0.85 CA1 (0.46) CA1CA2MMP1MMP2MMP9
SCHEMBL1498275 0.84 CA1 (0.45) CA1CA2MMP1MMP2MMP9
SCHEMBL27896526 0.83 CA1 (0.48) CA1CA2MMP1MMP2MMP9
SCHEMBL1498426 0.82 KDM1A (0.44) CA1CA2MMP1MMP2MMP9
SCHEMBL1498427 0.82 KDM1A (0.44) CA1CA2MMP1MMP2MMP9
SCHEMBL1498481 0.82 KDM1A (0.44) CA1CA2MMP1MMP2MMP9
SCHEMBL1498416 0.82 CA1 (0.47) CA1CA2MMP1MMP2MMP9
SCHEMBL1498405 0.81 MMP2 (0.43) CA1CA2MMP1MMP2MMP9
SCHEMBL1498320 0.80 CA1 (0.39) CA1CA2MMP1MMP2MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102762534-A Aryl sulfone derivatives as calcium channel blockers ZALICUS PHARMACEUTICALS LTD 2012-10-31 — — CN disclosed
US-20120245137-A1 ARYL SULPHONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS ZALICUS PHARMACEUTICALS LTD. (CA) 2012-09-27 — — US disclosed
US-20120245137-A1 ARYL SULPHONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS ZALICUS PHARMACEUTICALS LTD. (CA) 2012-09-27 — — US disclosed
US-20120245137-A1 ARYL SULPHONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS ZALICUS PHARMACEUTICALS LTD. (CA) 2012-09-27 — — US disclosed
EP-2477963-A1 ARYL SULPHONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS Zalicus Pharmaceuticals Ltd. (CA) 2012-07-25 — — EP disclosed
WO-2011035159-A1 ARYL SULPHONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS ZALICUS PHARMACEUTICALS LTD. (CA) 2011-03-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120245137-A1 ARYL SULPHONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS CACNA1I, CACNA1G, CACNA1A CA1 966/4885CA2 143/4885MMP1 3791/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback